Edoxaban HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414001

CAS#: 480448-29-1 (HCl)

Description: Edoxaban HCl is an anticoagulant medication and a direct factor Xa inhibitor.

Chemical Structure

img
Edoxaban HCl
CAS# 480448-29-1 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 414001
Name: Edoxaban HCl
CAS#: 480448-29-1 (HCl)
Chemical Formula: C24H31Cl2N7O4S
Exact Mass: 0.00
Molecular Weight: 584.520
Elemental Analysis: C, 49.32; H, 5.35; Cl, 12.13; N, 16.77; O, 10.95; S, 5.48

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 1229194-11-9 (tosylate hydrate)   480449-71-6 (tosylate)   480448-29-1 (HCl)   480449-70-5 (free base)  

Synonym: Edoxaban HCl; Edoxaban hydrochloride

IUPAC/Chemical Name: Ethanediamide, N1-(5-chloro-2-pyridinyl)-N2-((1S,2R,4S)-4-((dimethylamino)carbonyl)-2-(((4,5,6,7-tetrahydro-5-methylthiazolo(5,4-C)pyridin-2-yl)carbonyl)amino)cyclohexyl)-, hydrochloride (1:1)

InChi Key: ZQYCNCZOSSOOQR-QXXZOGQOSA-N

InChi Code: InChI=1S/C24H30ClN7O4S.ClH/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);1H/t13-,15-,17+;/m0./s1

SMILES Code: O=C(NC1=NC=C(Cl)C=C1)C(N[C@@H]2[C@H](NC(C(S3)=NC4=C3CN(C)CC4)=O)C[C@@H](C(N(C)C)=O)CC2)=O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 584.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548805/ PubMed PMID: 31644112.

2: Cervantes CE, Merino JL, Barrios V. Edoxaban for the prevention of stroke in patients with atrial fibrillation. Expert Rev Cardiovasc Ther. 2019 Apr;17(4):319-330. doi: 10.1080/14779072.2019.1598263. Epub 2019 Mar 27. Review. PubMed PMID: 30897988.

3: Pharmacoeconomic Review Report: Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK535088/ PubMed PMID: 30540394.

4: CADTH Canadian Drug Expert Committee Final Recommendation: Edoxaban: (Lixiana — Servier Canada Inc.): Indication: Venous Thromboembolic Events [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK534995/ PubMed PMID: 30540393.

5: Clinical Review Report: Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK535077/ PubMed PMID: 30540391.

6: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500740/ PubMed PMID: 29999799.

7: Linkins LA MD, MSc, FRCPC. Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism. BMJ Evid Based Med. 2018 Dec;23(6):230. doi: 10.1136/bmjebm-2018-111007. Epub 2018 Jun 29. Review. PubMed PMID: 29959155.

8: Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr. Available from http://www.ncbi.nlm.nih.gov/books/NBK475920/ PubMed PMID: 29341555.

9: Institute for Quality and Efficiency in Health Care. Edoxaban -- Benefit Assessment According to §35a Social Code Book V [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2015 Oct 28. Available from http://www.ncbi.nlm.nih.gov/books/NBK458399/ PubMed PMID: 29144699.

10: Hammwöhner M, Goette A. The safety of edoxaban for treating atrial fibrillation. Expert Opin Drug Saf. 2017 Nov;16(11):1295-1303. doi: 10.1080/14740338.2017.1372418. Epub 2017 Sep 18. Review. PubMed PMID: 28862063.

11: O'connor CT, Kiernan TJ, Yan BP. The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):725-739. doi: 10.1080/17425255.2017.1338274. Epub 2017 Jun 13. Review. PubMed PMID: 28571507.

12: Gibson CM, Finks SW. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape? Am J Med. 2017 Aug;130(8):900-906. doi: 10.1016/j.amjmed.2017.02.048. Epub 2017 Apr 6. Review. PubMed PMID: 28390791.

13: Scheen AJ, Lancellotti P. [Edoxaban (LIXIANA®) : new oral anticoagulant forthetreatment and secondary prevention of thromboembolic disease]. Rev Med Liege. 2016 Nov;71(11):517-524. Review. French. PubMed PMID: 28387109.

14: Weiss TW, Rohla M, Dieplinger B, Domanovits H, Fries D, Vosko MR, Gary T, Ay C. [Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper]. Wien Med Wochenschr. 2018 Apr;168(5-6):133-143. doi: 10.1007/s10354-017-0548-4. Epub 2017 Feb 24. Review. German. PubMed PMID: 28236004.

15: Curto A, Curto D, Sanchez J. Managing patients taking edoxaban in dentistry. J Clin Exp Dent. 2017 Feb 1;9(2):e308-e311. doi: 10.4317/jced.53431. eCollection 2017 Feb. Review. PubMed PMID: 28210454; PubMed Central PMCID: PMC5303336.

16: De Caterina R, Ageno W, Boriani G, Colonna P, Ghirarduzzi A, Patti G, Rossini R, Rubboli A, Schinco P, Agnelli G. Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. Adv Ther. 2017 Mar;34(3):620-637. doi: 10.1007/s12325-017-0488-9. Epub 2017 Feb 13. Review. PubMed PMID: 28194578; PubMed Central PMCID: PMC5350200.

17: Poulakos M, Walker JN, Baig U, David T. Edoxaban: A direct oral anticoagulant. Am J Health Syst Pharm. 2017 Feb 1;74(3):117-129. doi: 10.2146/ajhp150821. Review. PubMed PMID: 28122753.

18: Aspromonte N, Colivicchi F. Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure. Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):113-122. Epub 2016 Nov 18. Review. PubMed PMID: 27819149.

19: Minguet J, Sims HM, Smith KH, Bramlage P. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Expert Rev Clin Pharmacol. 2017 Jan;10(1):5-15. doi: 10.1080/17512433.2016.1258301. Epub 2016 Nov 17. Review. Erratum in: Expert Rev Clin Pharmacol. 2017 Jan;10 (1):1. PubMed PMID: 27817212.

20: AlHajri L, Jabbari S, AlEmad H, AlMahri K, AlMahri M, AlKitbi N. The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review. J Cardiovasc Pharmacol Ther. 2017 May;22(3):230-238. doi: 10.1177/1074248416675732. Epub 2016 Nov 2. Review. PubMed PMID: 27811198.